Evogene (NASDAQ: EVGN) reported Q4 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $580 thousand versus the consensus estimate of $893.33 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.